NEW YORK, NY / ACCESSWIRE / January 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Penumbra, Inc. (NYSE:PEN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/penumbra-inc-loss-submission-form?prid=12557&wire=1
Lead Plaintiff Deadline: March 16, 2021
Class Period: August 3, 2020 - December 15, 2020
Allegations against PEN include that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.
GoodRx Holdings, Inc (NASDAQ:GDRX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=12557&wire=1
Lead Plaintiff Deadline: February 16, 2021
Class Period: September 23, 2020 - November 16, 2020
Allegations against GDRX include that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
9F Inc. (NASDAQ:JFU)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/9f-inc-loss-submission-form?prid=12557&wire=1
Lead Plaintiff Deadline: March 22, 2021
Lawsuit on behalf of investors who purchased JFU securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company's August 14, 2019 initial public offering; and/or (2) between August 14, 2019 and September 29, 2020.
Allegations against JFU include that: (1) the purported value and benefits of the Company's financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited ("PICC") had been engaged in an ongoing contractual dispute regarding payment of service fees under their cooperation agreement; (2) the collectability of service fees owed to 9F by PICC under the cooperation agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; (4) as a result of the foregoing, the Company's platform, business model, reputation and financial results had been materially impaired; and (5) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong